Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/5/2019 |
| Start Date: | October 2015 |
| End Date: | December 2015 |
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects
The objectives of the study are to assess the safety and tolerability of a range of single
doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the
pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701
when administered as oral capsules to healthy subjects.
doses of IW-1701 when administered as oral capsules to healthy subjects, to determine the
pharmacokinetic profile and pharmacodynamics effects of a range of single doses of IW-1701
when administered as oral capsules to healthy subjects.
Inclusion:
- Between 18 and 60 years old at the Screening Visit;
- Women of childbearing potential must have a negative pregnancy test and must agree to
use double-barrier contraception;
- BMI > 18.5 and < 32.0 kg/m2 at the Screening Visit;
- In overall good health with no clinically significant laboratory, ECG, or physical
exam findings;
- Other inclusion criteria per protocol.
Exclusion:
- History of any clinically-significant medical condition;
- Other exclusion criteria per protocol.
We found this trial at
1
site
Click here to add this to my saved trials
